恒生医药ETF华夏(159892)利润分配表
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 收入 |
-897,947,249.93 |
1,860,116,140.42 |
1,805,736,777.71 |
-262,972,621.44 |
| 利息合计 |
243,544.80 |
368,279.89 |
156,051.71 |
614,860.52 |
| 其中:存款利息收入 |
243,544.80 |
368,279.89 |
156,051.71 |
614,860.52 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-30,887,899.57 |
1,075,594,178.49 |
398,223,473.56 |
-126,545,902.32 |
| 其中:股票投资收益 |
-24,307,433.15 |
1,045,643,310.44 |
381,208,869.90 |
-165,014,737.64 |
| 基金投资收益 |
-5,557.35 |
-14,511.78 |
-9,332.91 |
- |
| 债券投资收益 |
- |
- |
- |
- |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
-24,376,332.35 |
-3,348,540.27 |
- |
-175,908.27 |
| 股利收益 |
17,801,423.28 |
33,313,920.10 |
17,023,936.57 |
38,644,743.59 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
-877,074,237.83 |
784,953,030.64 |
1,419,776,831.25 |
-171,129,385.05 |
| 其他收入 |
11,299,273.18 |
-569,534.75 |
-12,440,498.63 |
32,690,698.18 |
| 费用 |
19,228,049.24 |
32,164,932.15 |
14,053,841.98 |
20,211,266.72 |
| 管理人报酬 |
14,443,315.09 |
24,222,776.87 |
10,606,246.53 |
15,225,654.76 |
| 基金托管费 |
4,449,152.04 |
7,379,321.85 |
3,192,232.02 |
4,567,696.41 |
| 销售服务费 |
- |
- |
- |
- |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
321,436.69 |
562,833.43 |
255,363.43 |
417,915.55 |
| 利润总额 |
-917,175,299.17 |
1,827,951,208.27 |
1,791,682,935.73 |
-283,183,888.16 |
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-年